DeCure for Developmental disorder of mental health
DeCure's autonomous Psychiatry AI scientist is researching a drug-repurposing hypothesis for developmental disorder of mental health — screening already-approved drugs against its 43-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDevelopmental disorder of mental health maps to a 43-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for developmental disorder of mental health is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
Rho GTPase activating protein 35 (ARHGAP35) — ARHGAP35 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gnpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3C5H · 1.8 Å · ligand PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER (GNP). Experimental structure, not a prediction.
What the evidence adds up to
A 1999 review of selective serotonin reuptake inhibitors (SSRIs) in intellectual disability notes that individuals with mental retardation may be particularly susceptible to dysfunction in the serotonin system, and that SSRIs appear to provide an important treatment option for target behaviours associated with anxiety and depression in this population. The review covers pharmacokinetics, pharmacodynamics, and potential effects on the developing brain, but provides no trial data, response rates, or sample sizes. A 2007 review of pharmacotherapy for pervasive developmental disorders (PDDs) states that few randomised double-blind treatment studies have been published, and very little is known about the long-term safety of these agents in this patient population. It concludes that some patients with PDDs may benefit acutely from pharmacotherapy, but many marketed psychotropic agents that hold promise have not been rigorously studied.
A 2002 textbook on child and adolescent psychopharmacology synthesises research on drug treatment for disorders including attention-deficit hyperactivity disorder, obsessive-compulsive disorder, major depression, schizophrenia, bipolar mania, aggression in pervasive developmental disorder, Tourette's syndrome, and substance abuse. It emphasises that treatments cannot be straightforwardly extrapolated from adult studies and discusses tolerability, efficacy, and appropriate use within a social and developmental context. No concrete numbers for survival, response rates, or sample sizes are given in the abstract. A 2018 text on child and adolescent psychotherapy reports that most youth with serious mental health issues do not receive evidence-based treatments and instead commonly receive untested, ineffective, or harmful treatments. It covers research-supported treatment packages for every major mental health issue in the DSM-5, including autism, psychosis, mania, depression, anxiety, trauma, eating, sleep, disruptive behaviour, and substance use.
Across these abstracts, the evidence base for drug repurposing in developmental disorders of mental health is thin. No abstract reports a randomised controlled trial with numerical outcomes for any specific drug. The 2007 review explicitly states that few double-blind studies exist and long-term safety data are absent. The 2018 text notes that most youth receive untested or ineffective treatments. What is still missing are adequately powered, randomised, double-blind trials with long-term follow-up, clear patient stratification by diagnosis and developmental stage, and funding to conduct such studies rather than relying on extrapolation from adult populations or small open-label reports.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cambridge University Press eBooks · 2002 · 44 citations
Practical Child and Adolescent Psychopharmacology
AbstractThe field of child and adolescent psychopharmacology is rapidly growing, but psychopharmacological treatments for children cannot be straightforwardly extrapolated from adult studies, which presents clinicians with assessment and prescribing challenges. This important book synthesises research findings about drug treatment of a broad range of psychiatric disorders in children, including attention-deficit hyperactivity disorder, obsessive-compulsive disorder, major depression, schizophrenia, bipolar mania, aggression in pervasive developmental disorder, Tourette's syndrome and substance abuse. They examine the issues of tolerability and efficacy, and appropriate use, within a social and developmental context. For each disorder, pharmacotherapy is discussed in the wider context of neurobiology, etiology, diagnosis and treatment. This will be essential reading for all mental health professionals to inform practice and improve patient outcomes.
Recent Advances in the Pharmacological Treatment of Pervasive Developmental Disorders
AbstractIntroduction. There is growing body of evidence to suggest that pharmacotherapy may be a rational form of intervention for some patients with pervasive developmental disorders (PDDs). The purpose of this article is to describe what is known about medication treatment for these patients. Methods. Published papers regarding the pharmacotherapy of PDDs were collected and reviewed. For each study, particular attention was paid to ascertaining patient characteristics, the medication doses employed, and medication tolerability. Results. There is evidence of varying methodological rigor to suggest that several medications may have a role in the treatment of patients with PDDs. However, to date, few randomized double-blind treatment studies have been published. In addition, there is very little known about the long-term safety of many of these agents in this patient population. Conclusions. Some patients with PDDs may benefit acutely from pharmacotherapy. Many marketed psychotropic agents that putatively hold promise for these patients have not been rigorously studied. More short-term and long-term research regarding the pharmacotherapy of patients with PDDs is needed.
Cambridge University Press eBooks · 2018 · 1 citations
Eating
AbstractEvery day, millions of children experience serious mental health issues, such as symptoms related to autism, psychosis, mania, depression, and anxiety. Moreover, many youth struggle with issues related to trauma, eating, sleep, disruptive behavior, and substance use. Most of these youth do not receive evidence-based treatments. Instead, they commonly receive untested, ineffective, and even harmful treatments. Child and Adolescent Psychotherapy presents the research-supported treatment packages and their individual components for every major mental health issue facing infants, children, and adolescents. Each chapter also identifies and analyzes other variables and resources that influence treatment: parents, assessment, comorbidity, demographics and medication. Useful resources are included for each mental health issued covered in the book. The chapters are organized in the same order as they appear in the DSM-5.
Cambridge University Press eBooks · 2018 · 0 citations
Anxiety
AbstractEvery day, millions of children experience serious mental health issues, such as symptoms related to autism, psychosis, mania, depression, and anxiety. Moreover, many youth struggle with issues related to trauma, eating, sleep, disruptive behavior, and substance use. Most of these youth do not receive evidence-based treatments. Instead, they commonly receive untested, ineffective, and even harmful treatments. Child and Adolescent Psychotherapy presents the research-supported treatment packages and their individual components for every major mental health issue facing infants, children, and adolescents. Each chapter also identifies and analyzes other variables and resources that influence treatment: parents, assessment, comorbidity, demographics and medication. Useful resources are included for each mental health issued covered in the book. The chapters are organized in the same order as they appear in the DSM-5.
Cambridge University Press eBooks · 2018 · 0 citations
Learning
AbstractEvery day, millions of children experience serious mental health issues, such as symptoms related to autism, psychosis, mania, depression, and anxiety. Moreover, many youth struggle with issues related to trauma, eating, sleep, disruptive behavior, and substance use. Most of these youth do not receive evidence-based treatments. Instead, they commonly receive untested, ineffective, and even harmful treatments. Child and Adolescent Psychotherapy presents the research-supported treatment packages and their individual components for every major mental health issue facing infants, children, and adolescents. Each chapter also identifies and analyzes other variables and resources that influence treatment: parents, assessment, comorbidity, demographics and medication. Useful resources are included for each mental health issued covered in the book. The chapters are organized in the same order as they appear in the DSM-5.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
